Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;175(2):225-228.
doi: 10.1007/s10517-023-05839-6. Epub 2023 Jul 19.

The Search for Single-Domain Antibodies Interacting with the Receptor-Binding Domain of SARS-CoV-2 Surface Protein

V S Aripov  1 , N V Volkova  2 , A V Taranin  3 , L V Mechetina  3 , N A Chikaev  3 , A M Nayakshin  3 , V S Nesmeyanova  2 , A A Isaeva  2 , Yu A Merkul'eva  2 , D V Shanshin  2 , S V Belenkaya  2 , A A Ilyichev  2 , D N Shcherbakov  2
Affiliations

The Search for Single-Domain Antibodies Interacting with the Receptor-Binding Domain of SARS-CoV-2 Surface Protein

V S Aripov et al. Bull Exp Biol Med. 2023 Jun.

Abstract

We performed a search for nanoantibodies that specifically interact with the receptor-binding domain (RBD) of the SARS-CoV-2 surface protein. The specificity of single-domain antibodies from the blood sera of a llama immunized with RBD of SARS-CoV-2 surface protein S (variant B.1.1.7 (Alpha)) was analyzed by ELISA. Recombinant trimers of the SARS-CoV-2 spike protein were used as antigens. In this work, a set of single-domain antibodies was obtained that specifically bind to the RBD of the SARS-CoV-2 virus.

Keywords: SARS-CoV-2; affinity selection; bacteriophage; phage library; single-domain antibodies.

PubMed Disclaimer

References

    1. Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods. 2007;324(1-2):13-25. https://doi.org/10.1016/j.jim.2007.04.008 - DOI - PubMed - PMC
    1. Gorchakov AA, Kulemzin SV, Guselnikov SV, Baranov KO, Belovezhets TN, Mechetina LV, Volkova OY, Najakshin AM, Chikaev NA, Chikaev AN, Solodkov PP, Larichev VF, Gulyaeva MA, Markhaev AG, Kononova YV, Alekseyev AY, Shestopalov AM, Yusubalieva GM, Klypa TV, Ivanov AV, Valuev-Elliston VT, Baklaushev VP, Taranin AV. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. Cell Discov. 2021;7(1):96. https://doi.org/10.1038/s41421-021-00340-8 - DOI - PubMed - PMC
    1. Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr. Opin. Investig Drugs. 2009;10(11):1212-1224. - PubMed
    1. Esmagambetov IB, Shcheblyakov DV, Egorova DA, Voronina OL, Derkaev AA, Voronina DV, Popova OA, Ryabova EI, Shcherbinin DN, Aksenova EI, Semenov AN, Kunda MS, Ryzhova NN, Zubkova OV, Tukhvatulin AI, Logunov DYu, Naroditsky BS, Borisevich SV, Gintsburg AL. Nanobodies are potential therapeutic agents for the Ebola virus infection. Acta Naturae. 2021;13(4):53-63. https://doi.org/10.32607/actanaturae.11487
    1. Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob. Agents Chemother. 2015;60(1):6-13. https://doi.org/10.1128/AAC.01802-15 - DOI - PubMed - PMC

Supplementary concepts

LinkOut - more resources